Palatin Technologies(PTN) - 2026 Q2 - Quarterly Report

Revenue and Financing - For the three and six months ended December 31, 2025, the company recognized $116,036 and $8,963,586 in collaboration and license revenue, compared to $0 for the same periods in 2024, indicating a significant increase due to the BI Agreement[155]. - Net cash provided by financing activities was $18,350,940 during the six months ended December 31, 2025, compared to $3,252,527 for the same period in 2024, highlighting successful equity financing efforts[166]. - The company entered into a sublicense agreement with Altanispac Labs, LLC, providing for upfront consideration of approximately $3,800,000, which will be recognized as license revenue in the quarter ending March 31, 2026[167][168]. Research and Development Expenses - Research and development expenses were $4,319,767 and $6,845,533 for the three and six months ended December 31, 2025, respectively, compared to $3,429,479 and $9,173,233 for the same periods in 2024, reflecting an increase in spending on MCR programs[156]. - Research and development expenses related to MCR programs were $2,290,073 and $3,260,702 for the three and six months ended December 31, 2025, respectively, compared to $1,888,065 and $5,969,102 for the same periods in 2024[157]. - Cumulative spending from inception to December 31, 2025, was approximately $311,900,000 on the Vyleesi program and approximately $254,500,000 on all other programs[159]. Operating Expenses - Selling, general and administrative expenses were $3,124,817 and $4,785,548 for the three and six months ended December 31, 2025, respectively, compared to $1,681,844 and $3,702,775 for the same periods in 2024, primarily due to increased compensation costs[160]. Cash Flow Management - Net cash used in operating activities was $6,426,227 for the six months ended December 31, 2025, compared to $11,863,319 for the same period in 2024, indicating improved cash flow management[164]. - The company expects existing cash and cash equivalents will be sufficient to fund operations through the next twelve months following the issuance of the financial statements[170]. Strategic Partnerships - The company is actively engaged in discussions with potential partners for non-obesity products to progress through development, approval, and commercialization[148].